.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 4,687,659

« Back to Dashboard

Claims for Patent: 4,687,659

Title: Diamide-DTPA-paramagnetic contrast agents for MR imaging
Abstract:Homologs of Diamide-DTPA-Paramagnetic compounds (such as diamido acetyl diethylene triamine triacetic acid) provide excellent contrast agents for magnetic resonance (MR) imaging. The magnetic dipole generated by the unpaired electron within the paramagnetic (PM) atom, causes a local reduction in the bulk magnetic field of the MR system. The resulting shorting of the T1 (spin lattice) relaxation time in the local hydrogen protons within the area of interest, causes an intense "free induction signal" and a corresponding modulation in the collected scanning data. The tissue or organ of interest appears on the MR display highlighted in white. Background tissue is displayed as darker or lower intensity greys. A surface highlighted image of the small and large intestine may be obtained by venous injection of the diamide contrast agent. The contrast agent is formed by replacing two carboxylic acids on the DTPA chelator with functional amide groups. The homologs enable the Diamide-DTPA-PM contrast agents to go into solution readily, and promote organ selectivity.
Inventor(s): Quay; Steven C. (Menlo Park, CA)
Assignee: Salutar, Inc. (Sunnyvale, CA)
Application Number:06/671,106
Patent Claims: 1. A chemically stable physiologically tolerable contrast agent in a solid state, for use in vivo solution during diagnostic magnetic resonance (MR) imaging, to enhance the MR image the region of interest of a subject within the MR scanning magnetic field, comprising:

a composition of matter of the form:

A-DTPA-PM(+Z),

where:

A-DTPA is an ethylene triamine pentaacetic acid chelator in which at least one of the five acetic acid groups has become a functional amide group A of the form:

A=--CONH--(CH.sub.2).sub.n-1 -CH.sub.3, wherein "n" is an integer up to 16 indicating the number of Carbon atoms in the Carbon-Hydrogen portion of the amide group A,

for functionally cooperating with the in vivo environment; and

PM(+Z) is a paramagnetic metal ion having an atomic charge of Z, securely chelated at a plurality of coordination points into the A-DTPA chelator to chemically isolate the PM(+Z) ion from the in vivo environment, for locally affecting the magnetic field of the MR system;

whereby the contrast agent causes a reduction in the T1 relaxation time near the region of interest within the subject.

2. The contrast agent of claim 1, wherein the composition of matter is a diamide of the form:

2A-DTPA-PM(+Z),

where:

2A-DTPA-PM(+Z) is ethylene triamine pentaacetic acid chelator in which two of the five acetic acid groups have been become a pair of functional amide groups A of the form:

A=--CONH--(CH.sub.2).sub.n-1 --CH.sub.3,

wherein n is an integer up to 16, indicating the number of Carbon atoms in the Carbon-Hydrogen portion of each amide group.

3. The contrast agent of claim 2, wherein Z=+3 and 2A-DTPA-PM(+3) is a molecule having a zero net charge.

4. The contrast agent of claim 2, wherein Z=+2 and the composition of matter has the form:

2A-IN-DTPA-PM(+2),

where:

IN is an inert cation of charge +1; and

2A-IN-DTPA-PM(+2) is a molecule having a zero net charge.

5. The contrast agent of claim 1, wherein the paramagnetic metal ion PM(+Z) within the composition of matter is at least one element selected from the group consisting of:

6. The contrast agent of claim 1, wherein the paramagnetic metal ion PM(+Z) within the composition of matter is at least one element selected from the group consisting of:

7. A chemically stable physiologically tolerable contrast agent in a pharmacological state, for in vivo use during diagnostic magnetic resonance (MR) imaging, to enhance the MR image of a subject within the MR scanning magnetic field, comprising:

a paramagnetic metal ion PM(+Z) having an atomic charge of Z for locally affecting the MR scanning magnetic field within the subject to reduce the T1 relaxation time thereof;

a triamine chelator DTPA' securely polar bonded around the PM(+Z) ion at a plurality of coordination points to provide a DTPA'-PM, and having the form: ##STR5## for chemically isolating the PM(+Z) ion from the in vivo environment; functional group means formed by an amide compound of the form

CONH.sub.2 --(CH.sub.2).sub.n-1 --CH.sub.3, wherein "n" is an integer indicating the number of Carbon atoms in the Carbon-Hydrogen portion of the amide compound,

for functionally cooperating with the in vivo environment, covalently bonded to the DTPA'-PM chelator forming an Amide-DTPA'-PM contrast agent; and

a pharmaceutically acceptable vehicle means for dispersing the Amide-DTPA'-PM contrast agent.

8. The contrast agent of claim 7, wherein the functional group means comprises:

a first amide group having n1 Carbon atoms in Carbon-Hydrogen portion, and covalently bonded to the DTPA'-PM chelator; and

a second amide group having n2 Carbon atoms in Carbon-Hydrogen portion, and covalently bonded to the DTPA'-PM chelator;

to form a Diamide-DTPA'-PM.

9. The contrast agent of claim 8, wherein n1 and n2 may by any whole integer from 0 to 16.

10. The contrast agent of claim 9, wherein the Diamide-DTPA'-PM is a homo-diamide in which n1=n2.

11. The contrast agent of claim 9, wherein the Diamide-DTPA'-PM is a hetero-diamide in which n1 is larger than n2.

12. The contrast agent of claim 7, wherein Z=+3 and the Amide-DTPA'-PM has a zero net charge.

13. The contrast agent of claim 7, wherein Z=+2 and the further comprises an inert cation IN having an atomic charge of +1 forming

Amide-IN(+1)-DTPA'-PM(+2) with a zero net charge.

14. The contrast agent of claim 7, wherein the vehicle means is a water solution.

15. The contrast agent of claim 14, further comprising water of hydration associated with the Carbon-Hydrogen portion to the amide compound.

16. The contrast agent of claim 7, wherein the paramagnetic metal ion (PM(+Z) is at least one element selected from the group consisting of:

17. The contrast agent of claim 7, wherein the paramagnetic metal ion PM(+Z) is at least one element selected from the group consisting of:

18. The contrast agent of claim 7, wherein the paramagnetic metal ion PM(+Z) is Fe(III).

19. The contrast agent of claim 7, wherein the paramagnetic metal ion PM(+Z) is Mn(II).

20. The contrast agent of claim 7, wherein the paramagnetic metal ion PM(+Z) is Co(II).

21. The contrast agent of claim 7, wherein the paramagnetic metal ion PM(+Z) is Gd(III).

22. The method of imaging a subject with a magnetic resonance (MR) imaging system employing an paramagnetic contrast agent, comprising the steps of:

Providing a physiologically tolerable contrast agent in the form:

2A-DTPA-PM(+Z),

where:

2A-DTPA is ethylene triamine pentaacetic acid chelator in which two of the five acetic acid groups have been become a pair of functional amide groups A of the form:

A=--CONH--(CH.sub.2).sub.n-1 --CH.sub.3, wherein n is an integer up to 16, indicating the number of Carbon atoms in the Carbon-Hydrogen portion of each amide group,

for functionally cooperating with the in vivo environment; and

PM(+Z) is a paramagnetic metal ion having an atomic charge of +Z, securely chelated at a plurality of coordination points into the 2A-DTPA chelator to chemically isolate the PM(+Z) ion from the in vivo environment, for locally affecting the magnetic field of the MR system;

introducing the 2A-DTPA-PM contrast agent into the subject;

Waiting for the amide functional groups to cooperate with the in vivo environment; and

Imaging the region of interest within a subject with the MR system to obtain a contrast agent enhanced MR image.

23. The method of imaging a subject as specified in claim 22, wherein the contrast agent is introduced by intravenous injection.

24. The method of imaging a subject as specified in claim 22, further comprising the initial step of dispersing the 2A-DTPA-PM contrast agent into a suitable carrier vehicle.

25. The method of imaging a subject as specified in claim 22, further comprising:

the initial step of providing data from a prior MR imaging: and

the final step of subtraction comparing the prior MR image with the current MR image.

26. The method of imaging a subject as specified in claim 22, wherein the region of interest is the gall bladder and the colon.

27. The method of imaging a subject as specified in claim 26, wherein the resulting image is a perspective image of the surface of the colon.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc